Details
September 24, 2020
12:00PM - 1:00PM
ENHERTU® (fam-trastuzumab deruxtecan-nxki): ONC deck
Hosted by AstraZeneca & Daiichi Sankyo
WEBINAR
|
On behalf of Daiichi Sankyo, Inc. and AstraZeneca, we cordially invite you to join us for an informative, expert-led discussion.
|
|
Please join us for a web-based discussion on
|
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki): ONC deck
|
|
This program will cover:
|
|
•
|
An FDA approved therapy for adult patients with HER2+ unresectable or metastatic breast cancer after two or more prior anti-HER2-based regimens in the metastatic setting*
|
|
•
|
Results from the Phase 2 clinical trial, DESTINY-Breast01
|
|
•
|
Key safety considerations for ENHERTU
|
|
•
|
Dosage and administration of ENHERTU
|
|
|
Program Details:
|
|
September 24, 2020
|
|
12:00 PM – 01:00 PM Eastern Daylight Time
|
|
Faculty:
|
|
Edward J. Crane, MD, Medical Oncologist
|
|
TriHealth Cancer Institute
|
|
CLICK HERE TO REGISTER
|
|
*
|
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
|
|
|
RSVP
|
|
Kyle Lefief or Laura Masztak
|
|
Representative Program Host
|
|
(586) 873-8767 or (269) 568-0283
|
|
BY
|
|
9/18/2020
|
|
|
This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation. In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs. Please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you may receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that compliance with such requirements can be ensured.
|
| |
Important Safety Information
|
|
| |
Indication
|
|
| |
ENHERTU is a HER2‑directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2‑positive breast cancer who have received two or more prior anti‑HER2‑based regimens in the metastatic setting.
|
|
| |
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
|
|
|
WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY
|
|
•
|
Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms.
|
|
•
|
Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.
|
|
| |
|
ENHERTU® is a registered trademark of Daiichi Sankyo Company, Limited.
© 2020 Daiichi Sankyo, Inc. and AstraZeneca.
US-43312 Last Updated 7/20
|
|
|
|
Printer-Friendly Version
Add to Calendar
aCLuDhaqizCaPxAftmqF167204
09/24/2020 12:00 PM
09/24/2020 01:00 PM
false
ENHERTU® (fam-trastuzumab deruxtecan-nxki): ONC deck
On behalf of Daiichi Sankyo, Inc. and AstraZeneca, we cordially invite you to join us for an informative, expert-led discussion.
Please join us for a web-based discussion on
ENHERTU® (fam-trastuzumab deruxtecan-nxki): ONC deck
This program will cover:
•
An FDA approved therapy for adult patients with HER2+ unresectable or metastatic breast cancer after two or more prior anti-HER2-based regimens in the metastatic setting*
•
Results from the Phase 2 clinical trial, DESTINY-Breast01
•
Key safety considerations for ENHERTU
•
Dosage and administration of ENHERTU
Program Details:
September 24, 2020
12:00 PM – 01:00 PM Eastern Daylight Time
Faculty:
Edward J. Crane, MD, Medical Oncologist
TriHealth Cancer Institute
CLICK HERE TO REGISTER
*
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
RSVP
Kyle Lefief or Laura Masztak
Representative Program Host
(586) 873-8767 or (269) 568-0283
BY
9/18/2020
This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation. In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs. Please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you may receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that compliance with such requirements can be ensured.
Important Safety Information
Indication
ENHERTU is a HER2‑directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2‑positive breast cancer who have received two or more prior anti‑HER2‑based regimens in the metastatic setting.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY
•
Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms.
•
Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.
ENHERTU® is a registered trademark of Daiichi Sankyo Company, Limited.© 2020 Daiichi Sankyo, Inc. and AstraZeneca.US-43312 Last Updated 7/20
WEBINAR